FXR0906 injection, a subsidiary of Fosun Pharmaceuticals (600196.SH), was approved for clinical trials

Zhitongcaijing · 2d ago

Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) issued an announcement. Recently, the company's holding subsidiary Fosun Pharmaceutical Industry Development (Shenzhen) Co., Ltd. (“Fosun Pharmaceutical (Shenzhen)”) received approval from the State Drug Administration to conduct clinical trials with FXR0906 injection (“FXR0906” for short) to treat hypertriglyceridemia. Fosun Pharmaceutical (Shenzhen) plans to conduct phase I clinical studies of this drug in China when conditions are met.

According to reports, FXR0906 is a liver-targeted siRNA low-interfering nucleic acid drug approved by the FXR0906 Group (that is, the company and holding subsidiaries/units, the same below), and the group enjoys the exclusive right to research, develop, register, produce and commercialize this drug within China, Hong Kong and Macao regions. FXR0906 reduces serum triglyceride levels through RNA interference technology and silencing APOC3 gene expression, thereby achieving treatment of hypertriglyceridemia.